Elevance Health (ELV) Q3 2026 (USD): adj. EPS 6.99 (exp. 4.70), Revenue 50.4bln (exp. 49.29bln); raises FY guidance

• The benefit expense ratio of 90.6 percent improved 70 basis points, driven by better performance in Medicare Advantage and Individual ACA compared to the prior year.

• Sees FY adj. EPS between 29.00 (exp. 27.26)

A beat of this size, with the medical cost ratio moving the right way and guidance raised, is the cleanest version of a managed care print, and this peer set has historically traded as a bloc on cost-trend signals: when one large name shows the benefit expense ratio improving in Medicare Advantage and the individual ACA book, the read-across to rivals with similar exposure has tended to be immediate, with the spread between winners and losers set by mix rather than by the headline EPS. The distinction worth drawing is between a beat driven by utilisation coming in below trend, which is repeatable, and one flattered by reserve development or one-offs, which typically gives back some of the move once the call is dissected. A raise anchored on a lower cost ratio carries more weight with the buy side than one built on revenue, since cost visibility has been the sector's recurring problem in recent reporting seasons. The follow-ons that matter are management commentary on utilisation and pricing into the next plan year, any colour on government program rates, and whether peers confirm or contradict the cost signal in their own prints over the following sessions.